IFF Half-Year Report 2022
Second Quarter 2022 Consolidated Financial Results:
- Reported net sales for the second quarter were $3.31 billion, an increase of 7% compared to the prior-year period. On a comparable basis, currency neutral sales increased 11%, led by double-digit growth in Nourish and Pharma Solutions.
- Income before taxes on a reported basis for the second quarter was $130 million. Adjusted operating EBITDA for the second quarter was $700 million, an increase of 3% from $679 million in the prior-year period. On a comparable basis2, currency neutral adjusted operating EBITDA increased 7%, driven by pricing actions and productivity gains.
- Reported earnings per share (EPS) for the second quarter was $0.43. Adjusted EPS excluding amortization was $1.54 per diluted share.
- • Cash flow from operations at the end of the second quarter was $(100) million, and free cash flow defined as cash flow from operations less capital expenditures totaled $(336) million, principally due to higher inventory value as a result of inflationary pressures. Net debt to credit adjusted EBITDA at the end of the second quarter was 4.4x.